03 Oct 2026, 15:02 IST
Alembic Pharmaceuticals Limited
Motilal Oswal (MOFSL) · Neutral
The report notes Alembic is expected to underperform peers with DF sales growth of 6.8% YoY owing to muted performance in acute and chronic segments, though it also expects 55% YoY US growth supported by Bosutinib exclusivity.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.